Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-237187
Filing Date
2022-09-02
Accepted
2022-09-02 08:30:29
Documents
5
Period of Report
2022-10-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A d392786ddef14a.htm DEF 14A 373664
2 GRAPHIC g392786sp1aaa.jpg GRAPHIC 1510
3 GRAPHIC g392786sp20a.jpg GRAPHIC 4660
4 GRAPHIC g392786sp20b.jpg GRAPHIC 3483
5 GRAPHIC g392786sp2aaa.jpg GRAPHIC 1776
  Complete submission text file 0001193125-22-237187.txt   391136
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40629 | Film No.: 221223276
SIC: 2836 Biological Products, (No Diagnostic Substances)